Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy


Karacin C., Eren T., Zeynelgil E., Imamoglu G. I. , Altinbas M., Karadag I., ...More

FUTURE ONCOLOGY, 2021 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume:
  • Publication Date: 2021
  • Doi Number: 10.2217/fon-2021-0597
  • Title of Journal : FUTURE ONCOLOGY
  • Keywords: cancer, chemotherapy, COVID-19, immunogenicity, immunotherapy, monoclonal antibody, safety, tumors, vaccine

Abstract

Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 mu g/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as 'immunogenicity.' Results: The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio: 0.830; p = 0.043). Conclusion: More than half of cancer patients receiving active systemic therapy developed immunogenicity.